Research ArticleAccepted Article
Reliability and Validity of Patient-Reported Outcomes Measurement Information System Short Forms in Ankylosing Spondylitis
Mark C. Hwang, Alexis Ogdie, Abin Puravath and John D. Reveille
The Journal of Rheumatology August 2019, jrheum.190201; DOI: https://doi.org/10.3899/jrheum.190201
Mark C. Hwang
Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, John P. and Kathrine G. McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX; Division of Rheumatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. This project was supported by the National Institute of Health PO1- AR052915. The project has not received financial support from any commercial interests. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, and Takeda and has received grants to the University of Pennsylvania from Pfizer and Novartis. JDR has served as a consultant for Janssen, Lilly, Novartis and Pfizer. AO is supported by K23 AR063764, R01 AR072363 and the Rheumatology Research Foundation. JDR is supported by the Spondyloarthritis Association of America. Address correspondence to Mark C. Hwang, M.D. John P. and Kathrine G. McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX. – 6431 Fannin MSB.5276, Houston, TX 77030. Email: Mark.C.Hwang@uth.tmc.edu
Alexis Ogdie
Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, John P. and Kathrine G. McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX; Division of Rheumatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. This project was supported by the National Institute of Health PO1- AR052915. The project has not received financial support from any commercial interests. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, and Takeda and has received grants to the University of Pennsylvania from Pfizer and Novartis. JDR has served as a consultant for Janssen, Lilly, Novartis and Pfizer. AO is supported by K23 AR063764, R01 AR072363 and the Rheumatology Research Foundation. JDR is supported by the Spondyloarthritis Association of America. Address correspondence to Mark C. Hwang, M.D. John P. and Kathrine G. McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX. – 6431 Fannin MSB.5276, Houston, TX 77030. Email: Mark.C.Hwang@uth.tmc.edu
Abin Puravath
Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, John P. and Kathrine G. McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX; Division of Rheumatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. This project was supported by the National Institute of Health PO1- AR052915. The project has not received financial support from any commercial interests. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, and Takeda and has received grants to the University of Pennsylvania from Pfizer and Novartis. JDR has served as a consultant for Janssen, Lilly, Novartis and Pfizer. AO is supported by K23 AR063764, R01 AR072363 and the Rheumatology Research Foundation. JDR is supported by the Spondyloarthritis Association of America. Address correspondence to Mark C. Hwang, M.D. John P. and Kathrine G. McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX. – 6431 Fannin MSB.5276, Houston, TX 77030. Email: Mark.C.Hwang@uth.tmc.edu
John D. Reveille
Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, John P. and Kathrine G. McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX; Division of Rheumatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. This project was supported by the National Institute of Health PO1- AR052915. The project has not received financial support from any commercial interests. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, and Takeda and has received grants to the University of Pennsylvania from Pfizer and Novartis. JDR has served as a consultant for Janssen, Lilly, Novartis and Pfizer. AO is supported by K23 AR063764, R01 AR072363 and the Rheumatology Research Foundation. JDR is supported by the Spondyloarthritis Association of America. Address correspondence to Mark C. Hwang, M.D. John P. and Kathrine G. McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX. – 6431 Fannin MSB.5276, Houston, TX 77030. Email: Mark.C.Hwang@uth.tmc.edu
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Reliability and Validity of Patient-Reported Outcomes Measurement Information System Short Forms in Ankylosing Spondylitis
Mark C. Hwang, Alexis Ogdie, Abin Puravath, John D. Reveille
The Journal of Rheumatology Aug 2019, jrheum.190201; DOI: 10.3899/jrheum.190201